rep 2165
Small moleculeexperimental
Clinical trial activity
1 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Mar 1, 2016 (NCT02565719)
Timeline
2010s
- Jan 1, 2016
Earliest Phase 2 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Hepatitis B virusINHIBITOR
Hepatitis B virus inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- rep 2165
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT02565719 | Phase 2 | Mar 1, 2016 | Replicor Inc., State University of Medicine and Pharmacy, Moldova |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Replicor Inc. | For profit | 1 | 1 | 1 | 2016 |
| State University of Medicine and Pharmacy, Moldova | Academic/Hospital | 1 | 0 | 1 | 2016 |
2 organizations
Page 1 / 1